MiR-103-3p targets the m<sup>6</sup> A methyltransferase METTL14 to inhibit osteoblastic bone formation.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33440070.
- Also identified by DOI 10.1111/acel.13298 and PMC identifier 7884043.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Impaired osteoblast function is involved in osteoporosis, and microRNA (miRNA) dysregulation may cause abnormal osteoblast osteogenic activity. However, the influence of miRNA on osteoblast activity and the underlying mechanisms remain elusive. In this study, miR-103-3p was found to be negatively correlated with bone formation in bone specimens from elderly women with fractures and ovariectomized (OVX) mice. Additionally, miR-103-3p directly targeted Mettl14 to inhibit osteoblast activity, and METTL14-dependent N<sup>6</sup> -methyladenosine (m<sup>6</sup> A) methylation inhibited miR-103-3p processing by the microprocessor protein DGCR8 and promoted osteoblast activity. Moreover, miR-103-3p inhibited bone formation in vivo, and therapeutic inhibition of miR-103-3p counteracted the decreased bone formation in OVX mice. Further, METTL14 was negatively correlated with miR-103-3p but positively correlated with bone formation in bone specimens from elderly women with fractures and OVX mice. Collectively, our results highlight the critical roles of the miR-103-3p/METTL14/m<sup>6</sup> A signaling axis in osteoblast activity, identifying this axis as a potential target for ameliorating osteoporosis.
Medical subject headings
- Bone Resorption
- Methyltransferases
- MicroRNAs
- Osteoblasts